Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.37 |
| ▸ | CDK2 | P24941 | 13/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 8/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25276302 | 0.92 | EPHX1 (0.38) | EPHX1DPP4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL7812041 | 0.91 | EPHX1 (0.53) | EPHX1DPP4SMN1; SMN2 | |
| SCHEMBL12669754 | 0.91 | EPHX1 (0.48) | EPHX1DPP4SMN1; SMN2LMNA | |
| SCHEMBL2145078 | 0.90 | EPHX1 (0.37) | EPHX1DPP4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL2145085 | 0.90 | EPHX1 (0.37) | EPHX1DPP4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL16224064 | 0.90 | EPHX1 (0.37) | EPHX1DPP4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL8495444 | 0.90 | EPHX1 (0.56) | EPHX1DPP4SMN1; SMN2 | |
| SCHEMBL3693380 | 0.87 | EPHX1 (0.39) | EPHX1DPP4CCNE1CDK2GSK3B | |
| SCHEMBL25284132 | 0.87 | EPHX1 (0.39) | EPHX1DPP4SMN1; SMN2CCNE1CDK2 | |
| SCHEMBL854419 | 0.86 | CHRM3 (0.42) | EPHX1DPP4SMN1; SMN2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| CN-109966294-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-105085491-B | Substituted benzazolyl compounds and its application method and purposes | 广东东阳光药业有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-109897038-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-06-18 | — | — | CN | disclosed |
| CN-109121414-A | Benzopyrazole compounds and analogs thereof | 拜奥克里斯特制药公司 | 2019-01-01 | — | — | CN | disclosed |
| CN-108707139-A | Amino-metadiazine compound and its preparation method and application | 北京浦润奥生物科技有限责任公司 | 2018-10-26 | — | — | CN | disclosed |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| CN-108175749-A | The solid dispersions of melt extrusion containing cell death inducer | 艾伯维爱尔兰无限公司 | 2018-06-19 | — | — | CN | disclosed |
| CN-103282025-B | Melt-extruded solid dispersions containing apoptosis-inducing agents | 艾伯维爱尔兰无限公司 | 2018-01-02 | — | — | CN | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| CN-1328247-C | N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists | MERCK & CO INC (US) | 2007-07-25 | — | — | CN | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| CN-1630633-A | N-biphenylmethylaminocycloalkane carboxamide derivatives with substituents on the methyl group thereof as bradykinin antagonists | MERCK & CO INC (US) | 2005-06-22 | — | — | CN | disclosed |
| CN-1176066-C | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ɪά��ʵ���� | 2004-11-17 | — | — | CN | disclosed |
| CN-1330067-A | 1,1-and 1,2-twice subsitituted cyclopropane compound, preparation method thereof and drug composite containing their | ADIR (FR) | 2002-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | EPHX1 2738/4885DPP4 615/4885SMN1; SMN2 4805/4885 |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | TERT, VIP, YWHAZ | EPHX1 1691/4885DPP4 225/4885SMN1; SMN2 2517/4885 |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | EPHX1 2860/4885DPP4 772/4885SMN1; SMN2 4802/4885 |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | EPHX1 950/4885DPP4 537/4885SMN1; SMN2 2329/4885 |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | EPHX1 1777/4885DPP4 3264/4885SMN1; SMN2 2038/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | EPHX1 2738/4885DPP4 615/4885SMN1; SMN2 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.